Navigation Links
Spring Bank Pharmaceuticals Awarded $3.9 Million RO1 NIH Grant to Advance Innovative Hepatitis Program
Date:5/5/2011

MILFORD, Mass., May 5, 2011 /PRNewswire/ -- Spring Bank Pharmaceuticals today announced it has been awarded an RO1 grant from the National Institute of Health, National Institute of Allergy and Infectious Diseases for the development of SB 9200, a novel, orally bioavailable agent for the treatment of Hepatitis B virus infection.  

Under the terms of this award, Spring Bank Pharmaceuticals will receive $3.9 million over five years in support of its development efforts.  This is the fourth Federally funded grant award Spring Bank Pharmaceuticals has received in support of it's Small Nucleic Acid Hybrid (SMNH) technology and brings the Company's total Federal support to more than $12 million.

"We are very pleased to receive this important grant award from the NIH to further develop SB 9200 for the treatment of Hepatitis B virus infections," said Douglas Jensen, CEO of Spring Bank Pharmaceuticals. " Hepatitis B infection is very widespread and has proven to be a very difficult disease to treat.  The NIH has made it clear that new types of drugs to treat Hepatitis B, such as SB 9200, are urgently needed."  According to R. P. Iyer, Ph.D., Chief Scientific Officer of Spring Bank Pharmaceuticals, "The NIH support for our HBV program validates our novel approach to treat this widespread disease.  SB 9200 holds great promise because it is a new class of potent orally bioavailable drug that works by an entirely novel mechanism of action and has demonstrated an excellent safety profile in a battery of in vitro and in vivo toxicology studies."

About Hepatitis B

Hepatitis B virus ("HBV") infects roughly one-third of the world's population, or more than two billion people. Of these, about 350 million become chronically infected, leading to progressive liver disease and approximately one million deaths each year.  Chronic infection with HBV can lead to the development of hepatocellular carcinoma ("HCC"), which has a five-year survival rate of less than 5%. Worldwide, there are about 1.2 million new cases of HCC annually, including about 15,000 in the US.

Despite the development of numerous antiviral drugs for HBV and HCV, effective treatment of hepatitis remains a substantially unmet medical need.  New treatment options are needed because current therapies do not eradicate the infection, suffer from the emergence of resistance and are poorly tolerated by many patients. SB 9200 is a potential breakthrough drug for the treatment of Hepatitis B because it has both direct antiviral and immune stimulating activities and acts via a novel host target. Further, SB 9200 is delivered orally, is well tolerated and can be used in combination with other classes of antivirals. By virtue of unique mechanism of action, SB 9200 is also being developed as novel treatment for Hepatitis C virus infection.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals is an IND-stage drug discovery company. Based on our proprietary platform technology, we are developing a pipeline of products representing a new class of pharmaceuticals, called Small Molecule Nucleic Acid Hybrids (SMNH) which have a wide range of therapeutic applications having multi-billion dollar market potential.  http://www.springbankpharm.com

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.

Contact: Don Mitchell (508) 473-5993 ext.102


'/>"/>
SOURCE Spring Bank Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
2. Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings
3. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
4. Discoverys Edge Spring Issue - http://discoverysedge.mayo.edu
5. DaVita Abstracts Accepted Into National Kidney Foundations 2009 Spring Symposium
6. Cold Spring Publishing Announces the Launch of a New Oncology Publication: The Journal of the Advanced Practitioner in Oncology
7. Sanovia Selected to Deliver PA-Logic(TM) Pharmaceutical Prior Authorization Platform to HealthSpring
8. Cold Spring Publishing, LLC, Changes Name to Harborside Press, LLC
9. Internal Fixation Systems to Sponsor and Exhibit at Wallstreet Spring Break Growth and Value Investor Conference in Fort Lauderdale, FL March 3-4, 2010
10. US Patent Allowed for Spring Action That Separates Protectus Innovative Safety Syringe From All Others
11. Tahoma, Colorado Springs and Salt Lake City Have the Highest Percentage of HIV Patients in the U.S. Who Are Left Untreated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016  Collagen Matrix, Inc., ("Collagen Matrix") the ... of collagen and mineral based medical devices for ... Bill Messer has joined the company as ... the growing portfolio of oral surgery, neurosurgery, orthopaedic ... joins the Collagen Matrix executive team as an ...
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
(Date:6/24/2016)... 24, 2016 Research and ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" report ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, ... Structural electronics involves electronic and/or electrical components ... replacing dumb structures such as vehicle bodies or ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
Breaking Medicine News(10 mins):